Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Shareholder Meeting (April 2024)
16 slides from Telix Pharmaceuticals's shareholder meeting presentation, Apr 5, 2024
Slide 1: General Meeting of Shareholders
Telix Manufacturing Solutions TLX250 SPECT image showing uptake in Belgium in CAIX-positive lesions General Meeting of TLX101-CDx PET image showing uptake in glioblastoma illustration showing TLX591 binding to PSMA Shareholders Telix Pharmaceuticals (ASX:TLX) 10.00am (Sydney time) 5 April 2024
Slide 2: Important information
Important information The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express
Slide 3: H Kevin McCann AO, Chairman
H Kevin McCann AO Chairman ©) Telix
Slide 4: Board of Directors
Board of Directors H Kevin McCann AO Christian Tiffany Olson Jann Skinner Andreas Kluge Mark Nelson Behrenbruch Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Director and Managing Director Director Director Director Director Chairman and Group CEO
Slide 5: Meeting agenda
Meeting agenda 01 Chairman’s address 02 CEO’s address 03 Formal items of business, including voting and questions
Slide 6: Chairman's address
General Meeting of Shareholders Chairman’s address H Kevin McCann AO
Slide 7: CEO's address
General Meeting of Shareholders CEO’s address Dr Christian Behrenbruch TLX250-CDx PET positive scan showing CAIX expression (Phase III ZIRCON study)
Slide 8: Our vision: global leadership in theranostics and precision medicine
Our vision: global leadership in theranostics and precision medicine Advancing Expanding Enhanced supply therapeutics, commercial chain and including portfolio, manufacturing, commencement of including European production Phase III prostate submission of facility + U.S. clinical Commercial Different
Slide 9: A global, vertically integrated business
A global, vertically integrated business Extensive innovation and manufacturing infrastructure • Liege (Quality control) Vancouver • Herstal (GMP3 and secondary packaging) Isotope production • Brussels South (GMP manufacturing / R&D Equipped to deliver (ARTMS)1 including alpha development) In-house
Slide 10: A strong foundation for growth
A strong foundation for growth R&D investment accelerating progress in four key areas Progress late-stage Commercialise therapeutic pipeline diagnostics ● Phase III ProstACT GLOBAL trial for prostate cancer therapy (TLX591) ● Planned launch of Zircaix®4 for kidney imaging and Pixclara 4 ● Phase II t
Slide 11: M&A strategy
M&A strategy Scaling-up a complete radiopharmaceutical ecosystem Adding sought-after resources, capabilities and value-creating assets Focus areas Supply chain and Clinical-stage pipeline Indication and manufacturing expansion franchise expansion Strategic • Advance Accretive assets in our next- Buy
Slide 12: Accelerating our vertical integration
Accelerating our vertical integration Supply chain and manufacturing Adds specialist capabilities and enhances isotope production • A commercial-stage radioisotope production • Specialty radiopharmaceutical development, technology firm, focus on radio-metals bioconjugation and contract manufacturing
Slide 13: QSAM Biosciences acquisition
QSAM Biosciences acquisition Clinical-stage pipeline expansion Highly complementary addition to Telix’s therapeutic pipeline About the Technology Synergies • “Next generation” bone seeking • Highly complementary to our urology targeted radiopharmaceuticals franchise • Based on a proven isotope platf
Slide 14: New technologies add depth in urology
New technologies add depth in urology Indication and franchise expansion Creating even “stickier” customer relationships • Precision-guided cancer surgery is a • Differentiated AI-platform with clinical fast-growing, high-value field decision support (CDSS) developed for PET/CT imaging • The urologi
Slide 15: Investment focus leads to key value creating catalysts
Investment focus leads to key value creating catalysts Four key areas Progress Commercialise Advance next Vertically of investment late-stage diagnostics and generation integrate supply therapeutic global expansion (alpha) of chain pipeline of Illuccix theranosticss Related upcoming milestones Pixcl
Slide 16: Thank you
Thank you 16
Telix Pharmaceuticals — Shareholder Meeting (April 2024) on 6ix